Bertis, a company specializing in developing proteomics-based precision medicine technology, said it has launched PASS (Pan-omics Analysis Service & Solution) service in the U.S. through its local subsidiary, Bertis Bioscience.

Bertis Bioscience has prepared to launch the PASS services after more than a year of preparation to assemble industry-recognized experts in mass spec-based proteomics and bioinformatics.

Bertis Bioscience will provide the PASS services at its CLIA Lab in San Diego, Calif. As part of the U.S. PASS launch, Bertis Bioscience will offer proof-of-principle studies for protein biomarker discovery using Seer’s proteograph and nanoparticle kits.

Bertis Biosciences had also signed its first proteomics-based analysis service agreement in the U.S. with the Salk Institute for Biological Studies, a San Diego-based non-profit life science research center known for discoveries in the fields of cancer, neuroscience, aging, immune-biology, and plant biology, in June.

Under the accord, Bertis Bioscience will provide proteomic data analysis to look for novel human disease biomarkers.

“Our technology and services have shown strong global competitiveness and receive favorable reception at various international conferences,” Bertis CEO Han Seung-man said. “We believe the U.S. launch will provide a stage for us to showcase our expertise globally and build our PASS business by serving world-class research institutions as a start.”

Pan-omics is the integration of complex “omics” datasets generated from the subfields of genomics, transcriptomics, proteomics, and metabolomics to increase the understanding of pathophysiology, diagnosis, and treatment of diseases.

PASS is an analysis solution leveraging Bertis’ pan-omics knowledge and know-how and its proprietary bioinformatics and AI technology to deliver analytical services, including core protein identification and biomarker discovery, drug development, and clinical research processes.